Lara K. Misegades
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lara K. Misegades has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Nancy E. Messonnier
2 shared publicationsStacey W. Martin
2 shared publicationsThomas A. Clark
2 shared publicationsJohn Talarico
1 shared publicationKathleen Harriman
1 shared publicationKathleen Winter
1 shared publication
Latest Publications
- Open Access
- 28 November 2012
- Published by American Medical Association (AMA) in JAMA
- Vol. 308 (20) , 2126-2132
Association of Childhood Pertussis With Receipt of 5 Doses of Pertussis Vaccine by Time Since Last Vaccine Dose, California, 2010
Pertussis remains a poorly controlled vaccine-preventable disease in the United States, despite a well-established childhood vaccination program and high coverage.1 Although infants have substantially higher rates of pertussis compared with other age groups, data from the National Notifiable Diseases Surveillance System reflect a recent increase in the number of reported pertussis cases among children aged 7 to 10 years. In 2010, this age group had the second highest incidence of pertussis in the United States.2 The changing epidemiology raises important questions about possible waning protection from the childhood acellular pertussis vaccine series.
- 28 November 2012
- Published by American Medical Association (AMA) in JAMA
- Vol. 308 (20) , 2126-2132
Open AccessAssociation of Childhood Pertussis With Receipt of 5 Doses of Pertussis Vaccine by Time Since Last Vaccine Dose, California, 2010
Pertussis remains a poorly controlled vaccine-preventable disease in the United States, despite a well-established childhood vaccination program and high coverage.1 Although infants have substantially higher rates of pertussis compared with other age groups, data from the National Notifiable Diseases Surveillance System reflect a recent increase in the number of reported pertussis cases among children aged 7 to 10 years. In 2010, this age group had the second highest incidence of pertussis in the United States.2 The changing epidemiology raises important questions about possible waning protection from the childhood acellular pertussis vaccine series.
- Open Access
- 7 August 2012
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (10) , 1432-1433
Estimating the Effectiveness of Acellular Pertussis Vaccines
To the Editor—In the 15 June 2012 issue of Clinical Infectious Diseases, Witt et al reported that vaccine effectiveness (VE) of acellular pertussis vaccines was 41% for children aged 2–7 years, 24% for 8- to 12-year-olds, and 79% for 13- to 18-year-olds [1]. The authors conclude that their data “confirms markedly lower than expected protection afforded by the pre-school series of acellular pertussis vaccinations in the 8–12 year age group” and poor durability of protection from the vaccine. While we agree that protection wanes over time, there are important limitations to the Witt et al analysis.
- 7 August 2012
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 55 (10) , 1432-1433
Open AccessEstimating the Effectiveness of Acellular Pertussis Vaccines
To the Editor—In the 15 June 2012 issue of Clinical Infectious Diseases, Witt et al reported that vaccine effectiveness (VE) of acellular pertussis vaccines was 41% for children aged 2–7 years, 24% for 8- to 12-year-olds, and 79% for 13- to 18-year-olds [1]. The authors conclude that their data “confirms markedly lower than expected protection afforded by the pre-school series of acellular pertussis vaccinations in the 8–12 year age group” and poor durability of protection from the vaccine. While we agree that protection wanes over time, there are important limitations to the Witt et al analysis.